Blueprint Medicines Corp - ESG Rating & Company Profile powered by AI
Full Sustainability analysis of Blueprint Medicines Corp are reached by logging in. Check the bottom of this webpage for potential risks for Blueprint Medicines Corp based on sector, geography and marketcap. This report of Blueprint Medicines Corp incorporates information from across the web as well as from public disclosures by Blueprint Medicines Corp.
Blueprint Medicines Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.1; made up of an environmental score of 5.3, social score of 8.0 and governance score of 8.0.
7.1
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 217 | Takara Bio Inc | 7.2 | High |
| 217 | Ultragenyx Pharmaceutical Inc | 7.2 | High |
| 224 | Blueprint Medicines Corp | 7.1 | High |
| 224 | Celularity Inc | 7.1 | High |
| 224 | Bilcare Ltd | 7.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Blueprint Medicines Corp have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose current and historical energy intensity?
Sign up for free to unlockDoes Blueprint Medicines Corp report the average age of the workforce?
Sign up for free to unlockDoes Blueprint Medicines Corp reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose its ethnicity pay gap?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose cybersecurity risks?
Sign up for free to unlockDoes Blueprint Medicines Corp offer flexible work?
Sign up for free to unlockDoes Blueprint Medicines Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Blueprint Medicines Corp conduct supply chain audits?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Blueprint Medicines Corp conduct 360 degree staff reviews?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose the individual responsible for D&I?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose water use targets?
Sign up for free to unlockDoes Blueprint Medicines Corp have careers partnerships with academic institutions?
Sign up for free to unlockDid Blueprint Medicines Corp have a product recall in the last two years?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose incidents of discrimination?
Sign up for free to unlockDoes Blueprint Medicines Corp allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Blueprint Medicines Corp issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose parental leave metrics?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose the pay ratio of women to men?
Sign up for free to unlockDoes Blueprint Medicines Corp support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Blueprint Medicines Corp reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Blueprint Medicines Corp involved in embryonic stem cell research?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose its waste policy?
Sign up for free to unlockDoes Blueprint Medicines Corp report according to TCFD requirements?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose energy use targets?
Sign up for free to unlockDoes Blueprint Medicines Corp disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Blueprint Medicines Corp have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Blueprint Medicines Corp
These potential risks are based on the size, segment and geographies of the company.
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.